Abstract:
Aims Prostate cancer (PC) is a significant health concern worldwide, and early detection is crucial for effective treatment. This study aimed to investigate the role of the hemoglobin-albumin-lymphocyte-platelet (HALP) score in detecting prostate cancer in patients undergoing transurethral resection of the prostate (TURP). Additionally, a comprehensive analysis was performed to explore clinical parameters associated with incidentally diagnosed prostate cancer post TURP. Methods A total of 131 patients with symptomatic bladder outlet obstruction who underwent TURP were included in the study. The patients were divided into two groups: those with benign prostatic hyperplasia (BPH) and those with incidental prostate cancer (IPC). The IPC group consisted of patients with both low-grade and high-grade IPC determined by the Gleason score. Demographic data, including age, race, medical history, body mass index, smoking and alcohol status, and family history of prostate cancer, were evaluated. The postoperative measurement of specimen weight and prostate-specific antigen (PSA) levels were also analyzed. Result Results revealed that approximately 50% of the patients had BPH, while the remaining 50% had IPC. Patients with IPC, particularly high-grade IPC, had significantly higher PSA levels and lower resected specimen weight compared to those with BPH. The HALP score, which incorporates hemoglobin (Hb), albumin, lymphocyte, and platelet levels, showed promise as a discriminatory tool for distinguishing between BPH and IPC, as well as between high-grade IPC and BPH/low-grade IPC. Logistic regression analysis identified increased PSA levels (p=0.02), decreased HALP score (p≤0.001), and smaller specimen weight (p=0.007) as independent predictive factors for IPC after TURP. Notably, the HALP score was the only significant independent predictive factor associated with high-grade IPC (p=0.004). Conclusion These findings contribute to the understanding of risk factors and diagnostic tools for incidentally detected prostate cancer in patients with bladder outlet obstruction undergoing TURP. The HALP score, along with PSA levels and specimen weight, can aid in the early detection and management of prostate cancer. Further research is warranted to validate these findings and explore the clinical utility of the HALP score in predicting prostate cancer outcomes.
摘要:
目的前列腺癌(PC)是全球重大的健康问题,早期发现对于有效治疗至关重要。本研究旨在探讨血红蛋白-白蛋白-淋巴细胞-血小板(HALP)评分在经尿道前列腺电切术(TURP)患者前列腺癌检测中的作用。此外,我们进行了一项综合分析,以探讨TURP术后与偶然诊断前列腺癌相关的临床参数.方法131例经TURP治疗的症状性膀胱出口梗阻患者纳入研究。患者分为两组:良性前列腺增生(BPH)和偶发前列腺癌(IPC)。IPC组由Gleason评分确定的低级别和高级别IPC患者组成。人口统计数据,包括年龄,种族,病史,身体质量指数,吸烟和酒精状况,前列腺癌家族史,进行了评估。还分析了术后标本重量和前列腺特异性抗原(PSA)水平的测量。结果结果显示,大约50%的患者患有BPH,而剩下的50%有IPC。IPC患者,特别是高级IPC,与BPH患者相比,PSA水平明显较高,切除的标本重量较低。HALP得分,其中包含血红蛋白(Hb),白蛋白,淋巴细胞,和血小板水平,显示出作为区分BPH和IPC的歧视性工具的希望,以及高级IPC和BPH/低级IPC之间。Logistic回归分析发现PSA水平升高(p=0.02),HALP评分降低(p≤0.001),和较小的标本重量(p=0.007)作为TURP后IPC的独立预测因素。值得注意的是,HALP评分是与高级别IPC相关的唯一有意义的独立预测因素(p=0.004).结论这些发现有助于了解膀胱出口梗阻患者行TURP时偶然发现的前列腺癌的危险因素和诊断工具。HALP得分,以及PSA水平和样本重量,可以帮助前列腺癌的早期发现和管理。需要进一步的研究来验证这些发现,并探索HALP评分在预测前列腺癌预后中的临床实用性。